• Citer

A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).

par Coleman, R;Biganzoli, Laura ;Canney, P A;Dirix, Luc Y;Mauriac, L;Chollet, P;Batter, V;Ngalula-Kabanga, E;Dittrich, C;Piccart-Gebhart, Martine
Référence European journal of cancer, 42, 7, page (882-887)
Publication Publié, 2006-05

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Auteur:	Coleman, R; Biganzoli, Laura; Canney, P A; Dirix, Luc Y; Mauriac, L; Chollet, P; Batter, V; Ngalula-Kabanga, E; Dittrich, C; Piccart-Gebhart, Martine
Informations sur la publication:	European journal of cancer, 42, 7, page (882-887)
Statut de publication:	Publié, 2006-05
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	Liposomal doxorubicin
	Metastatic breast cancer
MeSH keywords:	Adult
	Aged
	Aged, 80 and over
	Antibiotics, Antineoplastic -- administration & dosage
	Antibiotics, Antineoplastic -- adverse effects
	Breast Neoplasms -- drug therapy
	Dose-Response Relationship, Drug
	Doxorubicin -- administration & dosage
	Doxorubicin -- adverse effects
	Drug Administration Schedule
	Female
	Humans
	Infusions, Intravenous
	Liposomes -- therapeutic use
	Middle Aged
	Neoplasm Metastasis
Note générale:	Clinical Trial, Phase II
	Comparative Study
	Journal Article
	Randomized Controlled Trial
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:doi/10.1016/j.ejca.2005.12.011
	info:pii/S0959-8049(06)00042-6
	info:scp/33646485684
	info:pmid/16520033